- Global Pharma News & Resources

Anticancer Bioscience’s Dun Yang, PhD Has Been Named as a 2022 In Vivo Rising Leader

Chengdu, China, April 19, 2022 – Anticancer Bioscience (ACB), pioneers in synthetic lethal approaches to precision oncology, is delighted to announce that their Founder, President and CEO, Dun Yang, PhD has been named as a 2022 In Vivo Rising Leader.

With more than 25 years of basic research experience in biochemistry, cell and cancer biology and a track record of academic publications, Dun Yang has set his sights on translating scientific breakthroughs into novel therapies to help cancer patients worldwide. After completing his PhD in biochemistry at Columbia University, he worked and was mentored in one of the most prolific cancer research laboratories in the US, that of Nobel laureate Dr. J. Michael Bishop at the University of California, San Francisco. The two academic successes he can be credited with that stand out are the invention of the esiRNA method of gene silencing and pioneering research around MYC synthetic lethal drug interactions.

In 2016, Dun moved to China as a founding director of the J. Michael Bishop Institute of Cancer Research (MBICR). MBICR has now grown to where it is headquartered in the Tianfu International BioTown, Chengdu, China, employs a large team of basic and translational cancer researchers, and is advised by an advisory board comprised of nine preeminent scientists in the world. He also founded the company, Anticancer Bioscience (ACB), for the clinical translation of discoveries made at the MBICR to the clinic. ACB further employs an international team of chemists and drug and business development specialists, with employees in China, India, Australia, the United Kingdom and the United States.

ACB is a growing precision therapeutics company headquartered in Chengdu, China, with global research and development teams in India, Australia, the United Kingdom, and the United States. ACB is applying synthetic lethal approaches to develop targeted cancer therapies that have the potential to be much safer and more effective than current therapies. ACB has access to world-leading cancer biology expertise and proprietary drug discovery platforms that enable the company to identify novel compounds that can target both genetic and epigenetic vulnerabilities of cancer cells. ACB has bespoke chemical compound libraries and has invested in developing one of the world’s largest natural product libraries, providing a rich screening resource for potential cancer therapeutics.

Commenting on his nomination he said: “I am very grateful to have been nominated as one of In Vivo’s 30 Rising Leaders for 2022. I am very excited as to what the future holds for ACB and will continue to discover new scientific breakthroughs into novel therapies to help cancer patients worldwide.”

In Vivo's 30 Rising Leaders launched in 2020 and is updated annually. The 30 people spotlighted on the list are selected by their editorial team. The focus is on entrepreneurs and innovators who represent the next wave of creativity in health care. The list includes academics, CEOs of small and mid-sized companies, rising employees in larger biopharma and medtech businesses, as well as people doing exciting work to drive better health initiatives worldwide.



For further information please contact

At the company

Anticancer Bioscience


Media relations

Scius Communications

Sue Charles

+44 (0) 7968 726585


About Anticancer Bioscience

Anticancer Bioscience (ACB) is an international private company, commercializing discoveries emerging from China’s world-leading cancer research at the J. Michael Bishop Institute of Cancer Research. With pioneers in synthetic lethal approaches to precision oncology and experts in MYC biology and cell division, ACB was founded in 2016 in Chengdu, China. ACB is based on over 20 years of collaborative research between founder Dr. Dun Yang and his Nobel laureate mentor Dr. J. Michael Bishop. It has raised CNY131m (around USD21m) and has around 50 employees in Chengdu, China, Hyderabad, India, Sydney, Australia, St Andrews, UK, and San Francisco, USA.

Follow us on LinkedIn and Twitter.

Editor Details

Last Updated: 19-Apr-2022